Biostage CEO David Green reduces cash salary to $35,568; receives $264K stock option

Harvard Apparatus Regenerative Technology, Inc.

CEO David Green reduced annual base salary from $300,000 to $35,568 (minimum required by law).
Received nonqualified stock option valued at $264,432 (Black-Scholes) for the salary reduction difference.
Option vests monthly over 12 months; exercise price equals closing price on grant date (Jan 25, 2023).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.